BRAMPTON, ON, June 28, 2024 /CNW/ - Out of an abundance of caution, Loblaw Companies Ltd. is voluntarily recalling PC Cheddar Jalapeno Smokies, 1 kg, UPC: 060383200213, with a best before date of BB: 2024 JL 25. While there have been no reported cases of injury relating to the product, it is being recalled from the marketplace due to the possible presence of soft coloured plastic.
The product was sold at Real Canadian SuperstoreTM, FortinosTM, LoblawTM, Valu-MartTM, Your Independent Grocer, ZehrsTM, NofrillsTM, Atlantic SuperstoreTM, DominionTM, ProvigoMD, MaxiMD, AxepMD, IntermarcheMD, Extra FoodsTM, Real Canadian Wholesale ClubTM and Shoppers Drug Mart®.
All affected units have been removed from store shelves. Customers can return the product to the place of purchase and the customer service desk will provide a full refund.
We sincerely apologize for any inconvenience this recall may have caused. The health and safety of customers is our top concern.
SOURCE Loblaw Companies Limited - Public Relations
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...
